Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared a post on LinkedIn:
“ENGOT- OV44 / First Trial .
Use of Dostarlimab plus niraparib plus chemotherapy in first line Advanced Ovarian cancer has improved PFS .
Trial is Negative for OS ( headline does not say so )
It has complicated design.
It will be intresting to see the detail data once presented.”
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant.
